Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate

PALISADE BIO, INC.

Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.
Issued 1,536,885 shares at $1.952/share (5-day VWAP) for total $3.0 million to an affiliate of Iterative Health.
Funds support accelerated enrollment; shares sold in private placement exempt from registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.